Newbury Pharmaceuticals Future Growth
Future criteria checks 6/6
Newbury Pharmaceuticals is forecast to grow earnings and revenue by 130% and 62.4% per annum respectively.
Key information
130.0%
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 75.8% |
| Revenue growth rate | 62.4% |
| Future return on equity | 29.0% |
| Analyst coverage | Low |
| Last updated | 23 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 8/31/2026 | 141 | 17 | 9 | 15 | 1 |
| 8/31/2025 | 73 | 5 | 4 | 8 | 1 |
| 8/31/2024 | 37 | -15 | -27 | -24 | N/A |
| 5/31/2024 | 19 | -22 | -30 | -27 | N/A |
| 2/29/2024 | 23 | -17 | -29 | -26 | N/A |
| 11/30/2023 | 21 | -17 | -25 | -24 | N/A |
| 8/31/2023 | 10 | -19 | -24 | -23 | N/A |
| 5/31/2023 | 12 | -19 | -26 | -25 | N/A |
| 2/28/2023 | 7 | -18 | -26 | -21 | N/A |
| 11/30/2022 | 6 | -17 | -40 | -15 | N/A |
| 8/31/2022 | 6 | -15 | -39 | -15 | N/A |
| 5/31/2022 | 3 | -13 | -35 | -11 | N/A |
| 2/28/2022 | 3 | -12 | -35 | -15 | N/A |
| 11/30/2021 | 3 | -10 | -34 | -9 | N/A |
| 8/31/2021 | 3 | -6 | -30 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NEWBRY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).
Earnings vs Market: NEWBRY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NEWBRY is expected to become profitable in the next 3 years.
Revenue vs Market: NEWBRY's revenue (62.4% per year) is forecast to grow faster than the Swedish market (-0.04% per year).
High Growth Revenue: NEWBRY's revenue (62.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NEWBRY's Return on Equity is forecast to be high in 3 years time (29%)